Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

46.86 -1.66 (-3.42%)
Official Closing Price Updated: 7:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
76 77 Next >
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
From Bristol Myers Squibb
Via Business Wire
The 5-Letter Word Every Investor Should Memorize to Win in 2025
As volatility rattles tech giants, investors are rotating into value stocks for stability and upside. Discover why this five-letter word could be the key to winning in 2025. 
Via InvestorPlace
Topics Economy World Trade
3 Deeply Discounted Dividend Stocks to Buy Today
Via The Motley Fool
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements
EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors
Exelixis' Cabometyx gains FDA approval for advanced neuroendocrine tumors, while phase 3 data confirms sustained survival benefits in renal cancer. 
Via Benzinga
1 Large-Cap Stock on Our Watchlist and 2 to Brush Off
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth... 
Via StockStory
Topics Retirement
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
BRISTOL-MYERS SQUIBB CO (NYSE:BMY): good value for what you're paying.
BRISTOL-MYERS SQUIBB CO may be an undervalued stock option. NYSE:BMY retains a strong financial foundation and an attractive price tag. 
Via Chartmill
The Stock Market Hates Uncertainty & Loves To Climb A Wall-Of-Worry
In this video lesson, I review the overall market and a new swing position for Monday's session. 
Via Talk Markets
Topics ETFs Stocks / Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
2 High-Yield Dividend Stocks That Are Bargain Buys Right Now
Via The Motley Fool
Is BRISTOL-MYERS SQUIBB CO (NYSE:BMY) suited for dividend investing?
Why BRISTOL-MYERS SQUIBB CO (NYSE:BMY) is a Top Pick for Dividend Investors. 
Via Chartmill
Friday's session: top gainers and losers in the S&P500 index
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Europe Approves Bristol Myers' Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer
EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained efficacy. 
Via Benzinga
These S&P500 stocks are gapping in today's session
Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Friday and stay ahead of the market trends. 
Via Chartmill
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
From Bristol Myers Squibb
Via Business Wire
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst
H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets. 
Via Benzinga
Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025
From Bristol Myers Squibb
Via Business Wire
Bristol-Myers Squibb Co Chart Analysis
Technical analysis of the stock chart for BMY. 
Via Talk Markets
Topics Stocks / Equities
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)
From Brodsky & Smith LLC
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal
Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last close. Expected to close in Q2 2025. 
Via Benzinga
US Stocks Likely To Open Higher After Monday's Selloff: TSLA Stock Rebounds From Its Worst Fall In 5 Years After Trump Backs Musk, Analyst Says 'Pullbacks Are Normal'
U.S. stock futures rose on Tuesday following Monday's heavy selloff. Futures of all four benchmark indices surged in premarket trading. 
Via Benzinga
Topics Government
Which S&P500 stocks are moving on Monday?
Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Bristol Myers Unveils Positive Phase 3 Results for Sotyktu in Psoriatic Arthritis
Bristol Myers Squibb's Phase 3 POETYK PsA-2 trial shows Sotyktu improved psoriatic arthritis symptoms, meeting primary and secondary endpoints at Week 16. 
Via Benzinga
Why Is Protagonist Therapeutics Stock Trading Higher On Monday?
Protagonist and Johnson & Johnson's treatment for ulcerative colitis and psoriasis studies met key endpoints. 
Via Benzinga
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
The company is looking to take on Bristol Myers Squibb's Sotyktu in plaque psoriasis treatment. 
Via Investor's Business Daily
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
76 77 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.